27
Participants
Start Date
December 14, 2022
Primary Completion Date
March 31, 2023
Study Completion Date
August 15, 2023
SS109
27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.
Anhui Provincial Hospital, Hefei
Henan Provincial Cancer Hospital, Zhengzhou
Xiangya Hospital, Central South University, Changsha
Affiliated Hospital of Xuzhou Medical University, Xuzhou
Jiangxi Provincial People's Hospital, Nanchang
The First Affiliated Hospital of Shandong First Medical University, Jinan
The Second Hospital of Shanxi Medical University, Taiyuan
Xi'an Central Hospital, Xi’an
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin
The Second Affiliated Hospital of Kunming Medical University, Kunming
Jiangsu Gensciences lnc.
INDUSTRY